GlassScriptPhysician profile
Manish Kumar Dhamija
NPI 1699977413
$7,084.68
in general payments reported to CMS, 2019-2025
30 companies · $2,122 in 2025
The $2,122 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,494 · 2020: $640 · 2021: $170 · 2022: $426 · 2023: $742 · 2024: $1,492 · 2025: $2,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,256.21 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,503.84 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Qol Medical, LLC | $870.55 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $742.15 | 2019-2025 | Entyvio |
| Abbott Laboratories | $542.78 | 2019 | |
| Pfizer INC. | $432.92 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.55 | 2019-2025 | Xifaxan, Plenvu, Relistor |
| Janssen Biotech, INC. | $329.05 | 2019-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $274.25 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $229.12 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $204.37 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $202.55 | 2019-2024 | Dificid |
| Genzyme Corporation | $169.11 | 2024-2025 | |
| Ardelyx, INC. | $168.97 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $167.54 | 2025 | Dupixent |
| Boston Scientific Corporation | $164.45 | 2023 | Orcapod |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $157.13 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $124.64 | 2022 | |
| Intercept Pharmaceuticals, INC. | $82.08 | 2023-2025 | Ocaliva |
| Celgene Corporation | $81.36 | 2023-2024 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.57 | 2023-2024 | Cyltezo |
| Allergan, INC. | $47.04 | 2019 | |
| Ferring Pharmaceuticals INC. | $24.42 | 2022 | |
| Shionogi INC | $23.33 | 2020 | |
| Laborie Medical Technologies Corp. | $22.57 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Ipsen Biopharmaceuticals, INC | $18.09 | 2025 | |
| Vivus LLC | $16.52 | 2023 | Qsymia |
| Echosens North America, INC. | $16.18 | 2024 | Fibroscan |
| Shire North American Group INC | $11.93 | 2019 | |
| Alnylam Pharmaceuticals INC. | $11.49 | 2020 | |
| Braintree Laboratories, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Dhamija listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.